Search results for "hepatic"

showing 10 items of 609 documents

Interplay between glutamatergic and GABAergic neurotransmission alterations in cognitive and motor impairment in minimal hepatic encephalopathy.

2015

The cognitive and motor alterations in hepatic encephalopathy (HE) are the final result of altered neurotransmission and communication between neurons in neuronal networks and circuits. Different neurotransmitter systems cooperate to modulate cognitive and motor function, with a main role for glutamatergic and GABAergic neurotransmission in different brain areas and neuronal circuits. There is an interplay between glutamatergic and GABAergic neurotransmission alterations in cognitive and motor impairment in HE. This interplay may occur: (a) in different brain areas involved in specific neuronal circuits; (b) in the same brain area through cross-modulation of glutamatergic and GABAergic neur…

CerebellumMinimal hepatic encephalopathyGlutamic AcidNeurotransmissionSynaptic TransmissionCellular and Molecular NeuroscienceGlutamatergicmedicineHyperammonemiaAnimalsHumansGlutamatergic neurotransmissionGABAergic neurotransmissionHepatic encephalopathygamma-Aminobutyric AcidHepatic encephalopathyGABAA receptorbusiness.industryGlutamate receptorHyperammonemiaCognitionCell Biologymedicine.diseaseMotor Skills Disordersmedicine.anatomical_structureHepatic EncephalopathyCognitive functionCognition DisordersbusinessNeuroscience
researchProduct

Chemotherapy and Hepatic Steatosis: Impact on Postoperative Morbidity and Survival after Liver Resection for Colorectal Liver Metastases

2020

<b><i>Background:</i></b> Hepatic steatosis and chemotherapy in the treatment of colorectal liver metastases (CLM) are often linked to increased mortality and morbidity after liver resection. This study evaluates the influence of macrovesicular hepatic steatosis and chemotherapeutic regimes on graded morbidity and mortality after liver resection for CLM. <b><i>Methods:</i></b> A total of 323 cases of liver resection for CLM were retrospectively analysed using univariable and multivariable linear, ordinal and Cox regression analyses. The resected liver tissue was re-evaluated by a single observer to determine the grade and type of hepatic steat…

Chemotherapymedicine.medical_specialtybusiness.industryProportional hazards modelColorectal cancermedicine.medical_treatmentGastroenterologymedicine.diseaseGastroenterologyOxaliplatinInternal medicineMedicineSurgerySteatosisRisk factorMacrovesicular hepatic steatosisbusinessPacked red blood cellsResearch Articlemedicine.drugVisceral Medicine
researchProduct

AISF position paper on liver disease and pregnancy.

2016

Abstract The relationship between liver disease and pregnancy is of great clinical impact. Severe liver disease in pregnancy is rare; however, pregnancy-related liver disease is the most frequent cause of liver dysfunction during pregnancy and represents a severe threat to foetal and maternal survival. A rapid differential diagnosis between liver disease related or unrelated to pregnancy is required in women who present with liver dysfunction during pregnancy. This report summarizes the recommendation of an expert panel established by the Italian Association for the Study of the Liver (AISF) on the management of liver disease during pregnancy. The article provides an overview of liver disea…

Cholagogues and CholereticsViral HepatitisBudd-Chiari SyndromeChronic liver diseaseAdrenal Cortex HormoneGastroenterologyHyperemesis gravidarumLiver disease0302 clinical medicinePre-EclampsiaAdrenal Cortex HormonesCholelithiasisMED/12 - GASTROENTEROLOGIAPregnancyHyperemesis GravidarumEclampsiaCholelithiasiThiaminePregnancy Complications InfectiousCholagogues and CholereticSocieties Medical030219 obstetrics & reproductive medicineFatty liverUrsodeoxycholic AcidGastroenterologyCalcium Channel BlockersLiver diseases; Pregnancy; Gastroenterology; HepatologyPregnancy ComplicationAntihypertensive AgentItalyVitamin B ComplexBudd–Chiari syndromeLiver diseases; Pregnancy030211 gastroenterology & hepatologyFemaleCalcium Channel BlockerLiver diseaseHumanViral Hepatitis Vaccinesmedicine.medical_specialtyHELLP SyndromeHepatitis Viral HumanHELLP syndromeCholestasis Intrahepatic03 medical and health sciencesMagnesium SulfateInternal medicinemedicineHumansIntensive care medicineAntihypertensive AgentsLiver diseasesPregnancyEclampsiaHepatologybusiness.industrymedicine.diseasePregnancy ComplicationsFatty LiverPregnancy Liver disease Viral HepatitisPregnancy Complications InfectiouFluid TherapybusinessViral Hepatitis Vaccine
researchProduct

Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives

2019

The non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the most common cause of chronic liver disease as well as the first cause of liver transplantation. NAFLD is commonly associated with metabolic syndrome (MetS), and this is the most important reason why it is extremely difficult to treat this disease bearing in mind the enormous amount of interrelationships between the liver and other systems in maintaining the metabolic health. The treatment of NAFLD is a key point to prevent NASH progression to advanced fibrosis, to prevent cirrhosis and to prevent the development of its hepatic complications (such as liver decompensation and HCC) and even extrahepatic one. A part of the we…

CirrhosisHealth Toxicology and Mutagenesismedicine.medical_treatmentlcsh:MedicinePhysical exerciseDiseaseReviewLiver transplantationChronic liver diseaseHepatic ComplicationBioinformaticsmetabolic syndrome03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseasemedicineAnimalsHumans030304 developmental biology0303 health sciencesbusiness.industryFatty liverlcsh:RPublic Health Environmental and Occupational Healthnutritional and metabolic diseasesmedicine.diseasedigestive system diseasesmetabolic therapy030211 gastroenterology & hepatologyMetabolic syndromebusinessInternational Journal of Environmental Research and Public Health
researchProduct

The Impact of Antiviral Therapy and the Influence of Metabolic Cofactors on the Outcome of Chronic HCV Infection

2010

Natural history of HCV related chronic hepatitis is influenced and modified by many factors: virus features, coinfections and host characteristics. In particular, a peculiar genetic background of the host by conditioning the occurrence of intracellular metabolic derangements (i.e., insulin resistance) might contribute to accelerate the rate of progression to cirrhosis and eventually the occurrence of hepatocellular carcinoma (HCC) and death. Likely, direct interplays between virus genotype and host genetic background might be hypothesized at this level. Morbidity and mortality in cirrhosis is primarily associated with complications of liver cirrhosis (ascites, hepatic encephalopathy, jaundi…

CirrhosisHepatologybusiness.industryReview ArticleJaundicemedicine.diseaseVirusdigestive system diseasesHCV therapy natural historyInsulin resistanceInterferonHepatocellular carcinomaImmunologyAscitesmedicinelcsh:Diseases of the digestive system. Gastroenterologymedicine.symptomlcsh:RC799-869businessHepatic encephalopathymedicine.drugInternational Journal of Hepatology
researchProduct

Gender differences in chronic HBsAg carriers in Italy: Evidence for the independent role of male sex in severity of liver disease

2015

It has been shown that sexual hormones have an opposite effect on hepatic fibrosis progression and hepatocellular carcinoma development. Sex differences among 2,762 chronic HBsAg carriers consecutively referring Italian hospitals in 2001 and in 2007 have been evaluated, particularly focusing on the role of gender on severity of liver disease. The overall sex ratio (males/females) was 2.6. Females were more likely born abroad and new diagnosis cases; but less likely HIV coinfected. No sex difference was observed regarding coinfection with other hepatitis viruses. The sex ratio linearly increased with increasing severity of liver disease, being 1.3 in normal ALT, 2.8 in chronic hepatitis, 3.6…

Cirrhosisbusiness.industryHepatitis Bmedicine.diseaseVirologydigestive system diseasesVirusLiver diseaseInfectious DiseasesVirologyHepatocellular carcinomamedicineCoinfectionHepatic fibrosisbusinessSex ratioJournal of Medical Virology
researchProduct

Determination of queuosine derivatives by reverse-phase liquid chromatography for the hypomodification study of Q-bearing tRNAs from various mammal l…

2004

Three queuosine derivatives (Q-derivatives) have been found at position 34 of four mammalian so-called Q-tRNAs: queuosine (Q) in tRNA(Asn) and tRNA(His), mannosyl-queuosine (manQ) in tRNA(Asp), and galactosyl-queuosine (galQ) in tRNA(Tyr). An analytical procedure based on the combined means of purified tRNA isolation from liver cells and ribonucleoside analysis by reverse-phase high performance liquid chromatography coupled with real-time UV-spectrometry (RPLC-UV) was developed for the quantitative analysis of the three Q-derivatives present in total tRNA from liver tissues and liver cell cultures. Using this analytical procedure, the rates of Q-tRNA modification were studied in total tRNAs…

Clinical BiochemistryQueuosineRNA Transfer Amino AcylBiochemistryAnalytical Chemistrychemistry.chemical_compoundLiver Neoplasms ExperimentalRNA TransferNucleoside QTumor Cells CulturedAnimalsCells CulturedChromatography High Pressure LiquidChromatographyRNA Transfer AsnLiver cellRNAQueuineCell BiologyGeneral MedicineRibonucleosideRatsLiverchemistryBiochemistryCell cultureTransfer RNAHepatocytesHepatic stellate cellChickensJournal of Chromatography B
researchProduct

Profile of stress and toxicity gene expression in human hepatic cells treated with Efavirenz

2012

Hepatic toxicity and metabolic disorders are major adverse effects elicited during the pharmacological treatment of the human immunodeficiency virus (HIV) infection. Efavirenz (EFV), the most widely used non-nucleoside reverse transcriptase inhibitor (NNRTI), has been associated with these events, with recent studies implicating it in stress responses involving mitochondrial dysfunction and oxidative stress in human hepatic cells. To expand these findings, we analyzed the influence of EFV on the expression profile of selected stress and toxicity genes in these cells. Significant up-regulation was observed with Cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1), which indicated m…

CyclopropanesChemokineEfavirenzAnti-HIV AgentsPharmacologyMitochondrionmedicine.disease_causeCell Linechemistry.chemical_compoundStress PhysiologicalVirologyGene expressionmedicineHumansCXCL10PharmacologybiologyGene Expression ProfilingMolecular biologyBenzoxazinesMitochondriaOxidative StresschemistryAlkynesToxicityHepatocytesbiology.proteinHepatic stellate cellOxidative stressAntiviral Research
researchProduct

Autophagy as a rescue mechanism in efavirenz-induced mitochondrial dysfunction: a lesson from hepatic cells.

2011

Efavirenz (EFV) is the most widely used non-nucleoside reverse transcriptase inhibitor applied in highly active antiretroviral therapy (HAART), the combined pharmacological treatment of the human immunodeficiency virus infection. Its use has been associated with the development of several adverse events including hepatotoxicity. The molecular pathogenesis of this effect is poorly understood but recent reports have highlighted features of mitochondrial dysfunction in hepatic cells exposed to clinically relevant concentrations of EFV. In this study, we investigated the activation of autophagy and, in particular, mitophagy, in human hepatic cells exposed to EFV. We detected the presence of alt…

CyclopropanesEfavirenzCell SurvivalMitochondrionBiologyModels Biologicalchemistry.chemical_compoundMitophagymedicineAutophagyHumansMolecular BiologyReverse-transcriptase inhibitorAutophagyCell BiologyBenzoxazinesMitochondriachemistryApoptosisAlkynesImmunologyCancer researchHepatic stellate cellHepatocytesReverse Transcriptase InhibitorsHomeostasismedicine.drugAutophagy
researchProduct

Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survival-promoting autophagy

2011

Hepatotoxicity is a very common side effect associated with the pharmacological treatment of human immunodeficiency virus (HIV) infection and its pathogenesis is poorly understood. Efavirenz (EFV) is the most widely used nonnucleoside reverse transcriptase inhibitor administered for the control of HIV and some of its toxic effects in hepatic cells have been recently shown to display features of mitochondrial dysfunction. Here we studied the activation of autophagy and, in particular, mitophagy, the main mitochondrial turnover mechanism, in human hepatic cells treated with clinically relevant concentrations of this drug. EFV-treated cells had altered mitochondria, characterized by a relative…

CyclopropanesEfavirenzHepatologyAnti-HIV AgentsCell SurvivalMitochondrial TurnoverAutophagyVacuoleMitochondrionBiologyBenzoxazinesMitochondriaCell biologychemistry.chemical_compoundchemistryApoptosisAlkynesMitophagyAutophagyCancer researchHepatic stellate cellHumansChemical and Drug Induced Liver InjuryHeLa CellsHepatology
researchProduct